Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$1.21 USD
-0.01 (-0.82%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.20 -0.01 (-0.83%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
OVID 1.21 -0.01(-0.82%)
Will OVID be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OVID
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Other News for OVID
Is OVID lining up for a decline? Fell Below 20 Day Moving Average shows up after sinking 0.82%
Is OVID preparing to trend higher? Crossed Above 20 Day Moving Average shows up after soaring 5.17%
OVID forms 1,2,3 Pullback Bullish on September 17
Is OVID primed for downward momentum? Fell Below 20 Day Moving Average shows up after crashing 10.94%
Ovid Therapeutics Regains Nasdaq Compliance